NCT05635708 2026-04-15
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Active not recruiting
Clinical Trials
18 trialsNCT06745908 2026-04-15
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Recruiting
NCT07502300 2026-04-14
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07528274 2026-04-14
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT03744468 2026-04-02
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
Phase 1/2 Completed
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT06868732 2026-03-30
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Recruiting
NCT06897579 2026-03-23
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT07485920 2026-03-20
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
The Affiliated Hospital of Qingdao University
Phase 4 Not yet recruiting
NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
NCT04699188 2026-03-18
KontRASt-01
Novartis
Phase 1/2 Active not recruiting
NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting
NCT07120282 2026-03-09
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07432984 2026-02-25
FMT-LUNG
Samsung Medical Center
Phase 2 Not yet recruiting
NCT07416474 2026-02-20
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd.
Phase 3 Not yet recruiting
NCT05577702 2026-02-09
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Completed
NCT07383116 2026-02-03
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07131319 2026-02-02
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2/3 Recruiting